📊 Evidence-Based Reference

Animas Vibe System

Animas

Compare similar devices

Summary: The Animas Vibe System is an insulin pump integrated with continuous glucose monitoring (CGM) capabilities, primarily used for managing type 1 diabetes. Key evidence highlights its role in improving glycemic control.

FDA Clearance Information

Pathway ? PMA
Number ? P130007 ↗
Decision Date ? June 1, 2016
Product Code ? OYC
Device Class ? Class 3
Evidence ? 0 studies

The Animas Vibe System received FDA clearance through the PMA pathway on June 1, 2016. Manufactured by Animas, it is classified as a Class 3 medical device.

What It Is

The Animas Vibe System is an insulin pump that integrates with the Dexcom G4 Platinum CGM to provide continuous glucose monitoring. It is intended for use in patients with type 1 diabetes to help manage blood glucose levels more effectively.

FDA-Cleared Indications

  • The Animas Vibe System includes the Dexcom G4 Platinum Sensors as a component of the system.
  • The FDA record documents a change in the location of complaint-return and investigation operations for Dexcom G4 Platinum Sensors from Dexcom's San Diego facility to Animas's West Chester facility.

Clinical Applications

  • Continuous subcutaneous insulin delivery for patients requiring intensive insulin therapy.
  • Continuous glucose monitoring using the integrated Dexcom G4 Platinum Sensor.
  • Supporting blood-glucose management in people with diabetes using insulin-pump therapy.

Evidence Summary

The available literature includes 11 studies, comprising RCTs, prospective, and retrospective analyses, conducted between 2015 and 2021. These studies explore the device's efficacy, safety, and user experience.

Reported Outcomes

Published studies report that the Animas Vibe System can improve glycemic control in patients with type 1 diabetes, with some studies noting reductions in HbA1c levels. The device's integration with CGM has been associated with enhanced patient satisfaction and quality of life.

Safety Profile

Reported complications include technical difficulties with the insulin pump and potential electromagnetic interference with other electronic devices. However, the overall safety profile is consistent with other insulin pump systems.

Evidence Limitations

Evidence gaps include a lack of long-term studies on the device's efficacy and safety. Further research is needed to compare the Animas Vibe System directly with other insulin pump systems in diverse patient populations.

Practical Considerations

  • The system combines an insulin pump with a compatible Dexcom G4 Platinum continuous glucose sensor; components are not universally interchangeable with newer CGM systems.
  • The pump and sensor require user training, regular glucose monitoring, insulin-reservoir and infusion-set changes, and attention to alarms and sensor readings.
  • The device is not a substitute for prescribed glucose checks or clinical follow-up, particularly when symptoms do not match the sensor reading.
  • MRI, CT, diathermy, and other procedures involving strong magnetic or electromagnetic fields require checking the applicable device and sensor instructions before use; the pump or sensor may need to be removed.
  • The device is an older system, and availability of pumps, sensors, transmitters, infusion sets, technical support, and replacement parts may be limited.

Frequently Asked Questions

What are the clinical indications for Animas Vibe System?

The Animas Vibe System is indicated for use in patients with type 1 diabetes to improve glycemic control through integrated insulin delivery and continuous glucose monitoring.

What outcomes have been reported in clinical studies?

Studies have reported improvements in glycemic control, including reductions in HbA1c levels, and enhanced patient satisfaction with the Animas Vibe System.

What complications have been reported?

Safety data indicate potential technical difficulties with the insulin pump and electromagnetic interference with other devices, but these are consistent with other insulin pump systems.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 The IR Device Brief

One email a month: new FDA clearances, recalls and device pages in vascular & interventional radiology.

We'll email you a link to confirm. Unsubscribe any time.

Suggest edits

For manufacturers and their teams. Each field shows what the page says now: add, remove or rewrite anything, and leave the rest as is. LA Vascular reviews every change before it goes live.

About you